The primary endpoint was reached by 10 patients ( 69.7 % ) in the colesevelam group compared to 3 patients ( 27.3 % ) in the placebo group ( risk difference RD = .394 , 95 % CI :[ -0.012 ; 0.706 ] ; P = .0566 ) .